Abstract
Recent evidence indicates that gut microbiota dysbiosis impairs intestinal barrier function, induces endotoxemia, and consequently triggers systemic inflammatory cascades. Advances in gut microbiota research have further elucidated its critical role in the pathogenesis of diabetes and its complications. This review examines the relationship between diabetic cardiomyopathy and gut microbiota, delineating microbial metabolite-mediated and immunomodulatory influences on myocardial function, while proposing novel therapeutic strategies.